Study: Asante 2023, Journal of Diabetes Research
Therapeutic Benefit of Vernonia amygdalina in the Treatment of Diabetes and Its Associated Complications in Preclinical Studies
Citation
Asante DB, Wiafe GA (2023). Journal of Diabetes Research. PubMed id 38033739.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- Bush teas and herbal remedies (cerasee, bitter leaf) with medicines Tier B thin
C Diabetic rodents and cell and tissue models (preclinical review) (n=not applicable)
Narrative review of preclinical studies of Vernonia amygdalina (bitter leaf) in diabetes.
The review calls bitter leaf potently antidiabetic in preclinical work and appraises the evidence for future research. All the studies discussed are in animals and cells.
As recorded in this card: Asante DB, Wiafe GA (2023), Journal of Diabetes Research, [review]
Note: Preclinical only. My PubMed search for bitter leaf and diabetes in humans returned no human trial. It says nothing about safe amounts or interactions in people.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.